Company Overview
MOONLAKE IMMUNOTHERAPEUTICS
MLTXRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
-227M
2025 FY
Shares Outstanding
64M
2025 FY
EPS
-3.53USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1821586
Exchange
Nasdaq
Location
US